Recent cancer research and drug development have progressed beyond mere innovation, now focusing on delivering patient-centered clinical outcomes. This insight comes from the National New Drug Development Foundation’s analysis of the American Association for Cancer Research Annual Meeting 2026 (AACR 2026), held last month in San Diego.
Over 170 candidate substances unveiled; Verismo presents CAR-T clinical data
In a report released on Tuesday, the foundation stated that AACR 2026 showcased a shift in cancer research and drug development. The field is moving away from single-target (disease mechanism) and single-modality (technology type) approaches towards an integrated development paradigm. This new model simultaneously considers patient definitions, data integration, technology convergence, and clinical outcomes.
AACR 2026, held from April 17 to 22, brought together researchers and industry professionals from over 140 countries. Along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), it’s considered one of the world’s top three cancer conferences. The event serves as a critical platform for gauging trends and directions in cancer research and drug development.
Key topics at the conference included: precision medicine tailoring treatments to patient characteristics; low-dose strategies maintaining efficacy while reducing side effects; overcoming tumor microenvironment (TME) challenges; and leveraging artificial intelligence (AI) and spatial biology for analysis and treatment.
The foundation emphasized that precision medicine has evolved beyond simply choosing which target to pursue. They noted that even patients with the same target can respond differently to treatment based on factors like residual disease. This insight allows for a reinterpretation of clinical failures, suggesting they may result from inadequately defining the patient population where a target is truly effective.
The foundation also observed a shift in partnerships, now centered on data accessibility and AI capabilities rather than mere collaboration. They explained that AI has become an autonomous entity for hypothesis generation and drug design. Future competitiveness, they argue, will hinge on collaborative structures integrating data, technology, and clinical aspects, rather than individual technologies.
The foundation reported that biotech companies are diversifying their pipelines, moving away from reliance on specific technologies. While antibody-drug conjugates (ADCs) – often likened to precision-guided missiles for cancer cells – remain prominent, other modalities are gaining attention.
According to the foundation, competition in ADCs is intensifying, with a focus on optimizing payloads (the cancer-killing drugs) and targets. They also noted emerging possibilities in protein degradation therapies and highlighted radiation ligand therapy (RLT) as an expanding form of targeted treatment.
In immuno-oncology, the foundation reported an expansion beyond traditional CAR-T (chimeric antigen receptor T-cell) therapies to include approaches like tumor-infiltrating lymphocytes (TILs). This shift represents a move towards multi-modality strategies in cancer treatment.
The event showcased over 170 new cancer drug candidates, signaling a new phase in immuno-oncology research. This evolution marks a shift from simply prescribing anticancer drugs to developing strategies that maintain efficacy while minimizing side effects.
The foundation emphasized that cancer research and drug development are transitioning from single-target, single-modality approaches to an integrated paradigm. This new model considers patient characteristics and clinical outcomes simultaneously. They stressed that technology is expanding precision medicine to include dynamic systems accounting for residual disease and treatment resistance.
Several domestic pharmaceutical and biotech companies participated in the event, presenting their latest research. Notably, Algenomics and Verismo Therapeutics, a subsidiary of HLB Innovation, were selected for oral presentations. This selection underscores the completeness and academic significance of their research.
Verismo Therapeutics presented interim data from the Phase 1 clinical trial of their solid tumor CAR-T treatment candidate, SynKIR-110. Their presentation highlighted the candidate’s superior antitumor activity and improved safety profile compared to existing CAR-T therapies in blood cancer mouse models.